StoryCommercial
Cambrian unveils Amplifier Therapeutics, a Swedish pipeline company developing AMPK activator drugs
Cambrian BioPipeline companies
Cambrian Bio launched Amplifier Therapeutics to develop ATX-304, a pan-AMPK activator. Amplifier acquired Swedish company Betagenon, which discovered the compounds. AMPK is the cell's energy sensor, naturally switched on by exercise and fasting, and declines with age.
- ATX-304 enhances AMPK activation to increase ATP generation and energy production.
- Early clinical studies showed favorable safety and tolerability; Phase 1b proof-of-mechanism study planned.
- Broad potential across metabolic conditions, cardiovascular diseases, kidney diseases, and cancer.
- Amplifier acquired Betagenon AB, the Swedish company that discovered the AMPK activator compounds.